BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 2-97 IES

BIG 2-97 IES is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen.

The study found that in postmenopausal women, switching to exemestane after 2-3 years of tamoxifen significantly improves disease-free survival (New England Journal of Medicine 2004) and OS (ASCO 2006).

Coordinating group: ICCG

Patients accrual
Start date: February 1998
Closure date: February 2003
Target nr. of patients: 4740
Final accrual: 4743

Status: closed

ClinicalTrials.gov Identifier: NCT00038467

Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240